       Document 0820
 DOCN  M9620820
 TI    Versatile retroviral vectors for potential use in gene therapy.
 DT    9602
 AU    Hawley RG; Lieu FH; Fong AZ; Hawley TS; Division of Cancer Research,
       Sunnybrook Health Science Centre,; Toronto, Ontario, Canada.
 SO    Gene Ther. 1994 Mar;1(2):136-8. Unique Identifier : AIDSLINE
       MED/96050932
 AB    A set of retroviral vectors is described whose capacity for high
       efficiency transduction of functional genes into undifferentiated murine
       embryonic and haematopoietic cells makes them ideally suited for
       preclinical studies with murine models. Multiple unique cloning sites
       permit insertion of genes into the vectors such that no selectable
       marker exists or either the neomycin phosphotransferase (neo) gene, the
       hygromycin B phosphotransferase (hph) gene or the puromycin N-acetyl
       transferase (pac) gene is included as a dominantly acting selectable
       marker. Because the sequences in the viral gag region shown to improve
       the encapsidation of viral RNA have been modified to prevent viral
       protein synthesis and all env sequences have been removed to eliminate
       helper virus production by homologous recombination with packaging DNA,
       these vectors might prove useful in human gene therapy protocols.
 DE    Acetyltransferases/GENETICS  Animal  Base Sequence  Cells, Cultured
       DNA, Recombinant/GENETICS  Gene Deletion  *Gene Therapy  Genes, env
       Genetic Markers  *Genetic Vectors  Human  Mice  Molecular Sequence Data
       Phosphotransferases (Alcohol Group Acceptor)/GENETICS
       Retroviridae/*GENETICS  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

